What is the current valuation of the Therapeutic Proteins and Oral Vaccines Market?

The market valuation was 222.83 USD Billion in 2024. Read More

What is the projected market size for the Therapeutic Proteins and Oral Vaccines Market by 2035?

The projected valuation for 2035 is 554.0 USD Billion. Read More

What is the expected CAGR for the Therapeutic Proteins and Oral Vaccines Market during the forecast period 2025 - 2035?

The expected CAGR during this period is 8.63%. Read More

Which therapeutic class segment holds the highest market value in the Therapeutic Proteins sector?

The Antibodies segment holds the highest market value, with a range from 66.85 to 165.0 USD Billion. Read More

What are the key players in the Therapeutic Proteins and Oral Vaccines Market?

Key players include AbbVie, Amgen, Bristol-Myers Squibb, Johnson & Johnson, and Merck & Co. Read More

Which vaccine type is projected to have the highest market value by 2035?

The Subunit vaccine type is projected to reach a market value between 60.0 and 130.0 USD Billion. Read More

What disease indication segment is expected to show significant growth in the Therapeutic Proteins and Oral Vaccines Market?

The Infectious diseases segment is expected to grow significantly, with a projected range of 60.0 to 150.0 USD Billion. Read More

How does the Oral route of administration compare to other routes in terms of market value?

The Oral route is projected to have the highest market value, ranging from 80.0 to 200.0 USD Billion. Read More

What is the market value range for the Enzymes segment in the Therapeutic Proteins category?

The Enzymes segment has a market value range from 33.42 to 83.0 USD Billion. Read More

Which company is likely to lead the market in terms of innovation in therapeutic proteins?

Companies like Pfizer and Roche are likely to lead in innovation within the therapeutic proteins sector. Read More

Therapeutic Proteins Oral Vaccines Market

ID: MRFR/Pharma/26212-HCR

100 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Therapeutic Proteins And Oral Vaccines Market Research Report By Therapeutic Class (Antibodies, Enzymes, Hormones, Growth factors, Polypeptides), By Vaccine Type (Live attenuated, Inactivated, Toxoid, Subunit, Conjugate), By Disease Indication (Cancer, Cardiovascular diseases, Autoimmune diseases, Infectious diseases, Neurological disorders), By Route of Administration (Intravenous, Subcutaneous, Intramuscular, Oral, Topical) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Therapeutic Proteins Oral Vaccines Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Therapeutic Class (USD Billion)
  1. 4.1.1 Antibodies
  2. 4.1.2 Enzymes
  3. 4.1.3 Hormones
  4. 4.1.4 Growth factors
  5. 4.1.5 Polypeptides
2. 4.2 Healthcare, BY Vaccine Type (USD Billion)
  1. 4.2.1 Live attenuated
  2. 4.2.2 Inactivated
  3. 4.2.3 Toxoid
  4. 4.2.4 Subunit
  5. 4.2.5 Conjugate
3. 4.3 Healthcare, BY Disease Indication (USD Billion)
  1. 4.3.1 Cancer
  2. 4.3.2 Cardiovascular diseases
  3. 4.3.3 Autoimmune diseases
  4. 4.3.4 Infectious diseases
  5. 4.3.5 Neurological disorders
4. 4.4 Healthcare, BY Route of Administration (USD Billion)
  1. 4.4.1 Intravenous
  2. 4.4.2 Subcutaneous
  3. 4.4.3 Intramuscular
  4. 4.4.4 Oral
  5. 4.4.5 Topical
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Amgen (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
  10. 5.2.10 GSK (GB)
    1. 5.2.10.1 Financial Overview
    2. 5.2.10.2 Products Offered
    3. 5.2.10.3 Key Developments
    4. 5.2.10.4 SWOT Analysis
    5. 5.2.10.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY THERAPEUTIC CLASS
4. 6.4 US MARKET ANALYSIS BY VACCINE TYPE
5. 6.5 US MARKET ANALYSIS BY DISEASE INDICATION
6. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7. 6.7 CANADA MARKET ANALYSIS BY THERAPEUTIC CLASS
8. 6.8 CANADA MARKET ANALYSIS BY VACCINE TYPE
9. 6.9 CANADA MARKET ANALYSIS BY DISEASE INDICATION
10. 6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY THERAPEUTIC CLASS
13. 6.13 GERMANY MARKET ANALYSIS BY VACCINE TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY DISEASE INDICATION
15. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
16. 6.16 UK MARKET ANALYSIS BY THERAPEUTIC CLASS
17. 6.17 UK MARKET ANALYSIS BY VACCINE TYPE
18. 6.18 UK MARKET ANALYSIS BY DISEASE INDICATION
19. 6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
20. 6.20 FRANCE MARKET ANALYSIS BY THERAPEUTIC CLASS
21. 6.21 FRANCE MARKET ANALYSIS BY VACCINE TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY DISEASE INDICATION
23. 6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
24. 6.24 RUSSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
25. 6.25 RUSSIA MARKET ANALYSIS BY VACCINE TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY DISEASE INDICATION
27. 6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
28. 6.28 ITALY MARKET ANALYSIS BY THERAPEUTIC CLASS
29. 6.29 ITALY MARKET ANALYSIS BY VACCINE TYPE
30. 6.30 ITALY MARKET ANALYSIS BY DISEASE INDICATION
31. 6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
32. 6.32 SPAIN MARKET ANALYSIS BY THERAPEUTIC CLASS
33. 6.33 SPAIN MARKET ANALYSIS BY VACCINE TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY DISEASE INDICATION
35. 6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC CLASS
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY VACCINE TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DISEASE INDICATION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY THERAPEUTIC CLASS
42. 6.42 CHINA MARKET ANALYSIS BY VACCINE TYPE
43. 6.43 CHINA MARKET ANALYSIS BY DISEASE INDICATION
44. 6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
45. 6.45 INDIA MARKET ANALYSIS BY THERAPEUTIC CLASS
46. 6.46 INDIA MARKET ANALYSIS BY VACCINE TYPE
47. 6.47 INDIA MARKET ANALYSIS BY DISEASE INDICATION
48. 6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
49. 6.49 JAPAN MARKET ANALYSIS BY THERAPEUTIC CLASS
50. 6.50 JAPAN MARKET ANALYSIS BY VACCINE TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY DISEASE INDICATION
52. 6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC CLASS
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY VACCINE TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DISEASE INDICATION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
57. 6.57 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
58. 6.58 MALAYSIA MARKET ANALYSIS BY VACCINE TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY DISEASE INDICATION
60. 6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
61. 6.61 THAILAND MARKET ANALYSIS BY THERAPEUTIC CLASS
62. 6.62 THAILAND MARKET ANALYSIS BY VACCINE TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY DISEASE INDICATION
64. 6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
65. 6.65 INDONESIA MARKET ANALYSIS BY THERAPEUTIC CLASS
66. 6.66 INDONESIA MARKET ANALYSIS BY VACCINE TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY DISEASE INDICATION
68. 6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
69. 6.69 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC CLASS
70. 6.70 REST OF APAC MARKET ANALYSIS BY VACCINE TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY DISEASE INDICATION
72. 6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY THERAPEUTIC CLASS
75. 6.75 BRAZIL MARKET ANALYSIS BY VACCINE TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY DISEASE INDICATION
77. 6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
78. 6.78 MEXICO MARKET ANALYSIS BY THERAPEUTIC CLASS
79. 6.79 MEXICO MARKET ANALYSIS BY VACCINE TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY DISEASE INDICATION
81. 6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
82. 6.82 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC CLASS
83. 6.83 ARGENTINA MARKET ANALYSIS BY VACCINE TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY DISEASE INDICATION
85. 6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC CLASS
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY VACCINE TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE INDICATION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC CLASS
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY VACCINE TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DISEASE INDICATION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC CLASS
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY VACCINE TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DISEASE INDICATION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
99. 6.99 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC CLASS
100. 6.100 REST OF MEA MARKET ANALYSIS BY VACCINE TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY DISEASE INDICATION
102. 6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY VACCINE TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY VACCINE TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY DISEASE INDICATION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY DISEASE INDICATION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.2.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.3.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.4.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.5.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.6.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.7.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.8.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.9.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.10.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.11.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.12.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.13.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.14.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.15.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.16.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.17.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.18.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.19.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.20.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.21.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.22.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.23.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.24.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.25.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.26.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.27.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.28.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.29.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.30.2 BY VACCINE TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Therapeutic Class (USD Billion, 2025-2035)

Antibodies
Enzymes
Hormones
Growth factors
Polypeptides

Healthcare By Vaccine Type (USD Billion, 2025-2035)

Live attenuated
Inactivated
Toxoid
Subunit
Conjugate

Healthcare By Disease Indication (USD Billion, 2025-2035)

Cancer
Cardiovascular diseases
Autoimmune diseases
Infectious diseases
Neurological disorders

Healthcare By Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Intramuscular
Oral
Topical

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”